BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.18 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.14 -0.3 -1.32 -2.02 -2.35 Dividends USD Payout Ratio % * Shares Mil 16.0 15.0 15.0 16.0 17.0 Book Value Per Share * USD 2.93 1.9 3.59 Free Cash Flow Per Share * USD -0.67 -1.58 Return on Assets % -666.52 -85.83 -82.48 -64.49 Financial Leverage (Average) 1.12 1.35 1.18 Return on Equity % -101.67 -100.23 -77.51 Return on Invested Capital % -101.67 -97.19 -75.98 Interest Coverage Current Ratio 0.010 0.38 9.26 4.03 6.81 Quick Ratio 0.38 9.16 3.83 6.53 Debt/Equity 0.04 0.010